Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NASAREL vs NASONEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.
Corticosteroid with anti-inflammatory activity; binds to glucocorticoid receptors, inhibiting inflammatory mediators like prostaglandins and leukotrienes.
Seasonal and perennial allergic rhinitis,Nonallergic rhinitis,Nasal polyps (off-label)
FDA: Treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children ≥2 years; treatment of nasal polyps in adults ≥18 years.,Off-label: Acute sinusitis, nonallergic rhinitis.
2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.
Mometasone furoate 200 mcg per day as 2 sprays (50 mcg/spray) in each nostril once daily. May reduce to 100 mcg per day (1 spray per nostril once daily) if symptoms controlled. Maximum 200 mcg per day.
Terminal half-life approximately 15-25 minutes for flunisolide (the active ingredient in NASAREL) in the systemic circulation after intranasal administration. Clinically, the half-life is short, reducing the risk of systemic accumulation but requiring twice-daily dosing for consistent effect.
The terminal elimination half-life of mometasone furoate following intranasal administration is approximately 5.8 hours (range 2.7–11.5 hours) in adults, reflecting rapid clearance from systemic circulation.
Primarily hepatic via CYP3A4 isoform; undergoes extensive first-pass metabolism.
Hepatic metabolism via CYP3A4; desonide undergoes extensive biotransformation.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <30% of dose. Fecal elimination minimal (<5%).
Mometasone furoate is extensively metabolized in the liver, primarily via CYP3A4, and metabolites are excreted mostly in feces (approximately 74%) and to a lesser extent in urine (approximately 8%).
Approximately 40-50% bound to plasma proteins, primarily albumin.
Mometasone furoate is approximately 98-99% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 1.4–2.0 L/kg after IV administration, indicating extensive tissue distribution. For intranasal use, the Vd is not directly applicable but reflects systemic exposure if absorbed.
The volume of distribution at steady state (Vss) is 332 L (approximately 4.5 L/kg for a 70 kg adult), indicating extensive tissue distribution.
Intranasal: Systemic bioavailability is approximately 21% (range 10-50%) due to first-pass metabolism. Oral bioavailability is <1% due to extensive hepatic first-pass effect. The drug is administered intranasally for local effect with low systemic exposure.
Intranasal bioavailability is less than 1% due to low systemic absorption; oral bioavailability is negligible (less than 1% due to extensive first-pass metabolism).
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment. No GFR-based guidelines exist.
No dose adjustment required for hepatic impairment.
No specific dose adjustment recommended for hepatic impairment. No Child-Pugh based modifications established.
Children 6-11 years: 1 spray in each nostril once daily; maximum 4 sprays/day. Children ≥12 years: same as adult.
Ages 2–11 years: 1 spray (50 mcg) per nostril once daily (100 mcg total). Ages 12–17 years: same as adult (2 sprays per nostril once daily, 200 mcg total).
No specific dose adjustment; use lowest effective dose.
No specific dose adjustment required. Use same as adult dosing. Monitor for local adverse effects (e.g., epistaxis, nasal irritation) which may be more common in elderly.
None
None.
May cause epistaxis, nasal septal perforation, or nasal mucosal ulceration,Potential for systemic corticosteroid effects with prolonged use,May suppress hypothalamic-pituitary-adrenal (HPA) axis, especially at higher doses,Increased susceptibility to infections; avoid in active untreated infections,Use with caution in patients with tuberculosis, ocular herpes simplex, or untreated fungal/bacterial infections
Nasal corticosteroid withdrawal symptoms upon discontinuation,Risk of adrenal suppression with high doses or prolonged use,Increased susceptibility to fungal infections (e.g., Candida albicans),Potential for growth retardation in children,Hoarseness, epistaxis, and nasal septal perforation with misuse
Hypersensitivity to flunisolide or any component of the formulation,Untreated localized nasal infections (e.g., bacterial, fungal, viral)
Hypersensitivity to any component,Untreated nasal infection (e.g., herpes simplex),Recent nasal surgery or trauma (until healing completed)
No significant food interactions known. May take without regard to meals. Avoid consuming grapefruit or grapefruit juice as it may increase systemic exposure (weak CYP3A4 interaction).
No clinically significant food interactions. Avoid alcohol if it exacerbates rhinitis symptoms.
FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (flunisolide) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk of cleft palate; avoid systemic absorption by using minimal effective dose. Second and third trimesters: No specific risks reported; monitor for fetal adrenal suppression if used chronically at high doses.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic. There are no adequate and well-controlled studies in pregnant women. Nasonex (mometasone furoate) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Limited data, risk cannot be ruled out. Second trimester: Use with caution if benefit outweighs risk. Third trimester: Potential for fetal adrenal suppression with prolonged use.
It is not known whether flunisolide is excreted in human milk. Because many corticosteroids are excreted in human milk, caution should be exercised when Nasarel is administered to a nursing woman. M/P ratio not available. Use with caution; consider using lowest effective dose and monitoring infant for signs of adrenal suppression.
It is not known whether mometasone furoate is excreted in human milk. Because many corticosteroids are excreted in human milk, caution should be exercised when Nasonex is administered to a nursing woman. M/P ratio: Not available.
No specific dose adjustments required due to pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize systemic absorption. No change in hepatic metabolism or renal clearance expected for intranasal flunisolide.
No dose adjustment is recommended based on pharmacokinetic changes in pregnancy. Systemic absorption of intranasal mometasone is minimal; thus, significant pharmacokinetic changes are not expected. Use the lowest effective dose for the shortest duration.
For best results, advise patients to blow nose gently before use. Avoid spraying directly onto nasal septum to reduce risk of epistaxis and septal perforation. Tilt head forward slightly and spray away from septum. Priming pump (6 sprays or until fine mist appears) is essential if not used for >7 days. Monitor nasal mucosal integrity during long-term use. May cause transient stinging or burning; consider co-administration with saline spray if irritation persists.
Use the lowest effective dose for the shortest duration. Primarily for seasonal allergic rhinitis; not for acute sinusitis. Monitor for epistaxis and nasal irritation. May cause headache or pharyngitis. Avoid in patients with recent nasal surgery or trauma. Consider intranasal corticosteroids as first-line for moderate to severe allergic rhinitis.
Use exactly as prescribed; do not exceed recommended dose.,Shake bottle gently before each use.,Prime pump by spraying 6 times into air if new or not used for 7 or more days.,Blow nose to clear nasal passages before administration.,Insert nozzle into nostril, tilt head slightly forward, and spray away from the nasal septum.,Avoid spraying directly onto the nasal septum.,Rinse nozzle with warm water after each use and replace cap tightly.,Do not share the medication with others.,If using other nasal sprays, use them at different times (separated by 10-15 minutes).,Contact doctor if symptoms do not improve after 3 weeks or if nasal bleeding occurs.
Use regularly for best results; onset of action may take several days.,Prime the spray before first use or if not used for more than 2 weeks.,Aim spray away from nasal septum to reduce risk of nosebleeds.,Do not use in eyes or mouth.,Inform your doctor if you have a nasal infection or recent nasal surgery.,Side effects may include headache, nosebleed, or throat irritation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NASAREL vs NASONEX, answered by our medical review team.
NASAREL is a Intranasal Corticosteroid that works by Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.. NASONEX is a Intranasal Corticosteroid that works by Corticosteroid with anti-inflammatory activity; binds to glucocorticoid receptors, inhibiting inflammatory mediators like prostaglandins and leukotrienes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NASAREL and NASONEX depend on the specific clinical indication. These are both Intranasal Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NASAREL is: 2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.. The standard adult dose of NASONEX is: Mometasone furoate 200 mcg per day as 2 sprays (50 mcg/spray) in each nostril once daily. May reduce to 100 mcg per day (1 spray per nostril once daily) if symptoms controlled. Maximum 200 mcg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NASAREL and NASONEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NASAREL is classified as Category C. FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (fl. NASONEX is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic. There are no adequate and well-controlled studies in pregnant women. Nasonex (mometa. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.